According to a recent systematic review, three different classes of antihyperglycemic drugs have shown promise in treating NAFLD: SGLT2 inhibitors, peroxisome proliferator-activated receptor (PPAR) agonists, and glucagon-like peptide 1 (GLP-1) receptor agonists. Specifically, the researchers found that SGLT2 inhibitors (mostly dapagliflozin and empagliflozin) reduced liver fat content.
Learn more about SGLT2 inhibitors.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: B.S. Anand. Rapid Review Quiz: Nonalcoholic Fatty Liver Disease (NAFLD) - Medscape - May 27, 2022.